• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [25305 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2026     Swiss Federal Office of Public Health (FOPH) Injection therapies with corticosteroids for chronic tendinopathy or enthesopathy
2026     Swiss Federal Office of Public Health (FOPH) Superficial/deep heat in physiotherapy for musculoskeletal conditions
2026     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Reinforced foster homes]
2026     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Efficacy and safety of emotional freedom techniques for the treatment of anxiety, depression and post traumatic stress disorders]
2026     Health Technology Wales (HTW) Rapid antigen detection tests for group A streptococcal infections to treat people with a sore throat in the community pharmacy setting
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Local hyperbaric oxygen therapy for diabetic foot ulcers]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) – Addendum to Project A25-87]
2025     Ontario Health Home-based heated humidified high-flow therapy for respiratory conditions
2025     Ontario Health DNA methylation-based classification for central nervous system tumours
2025     Ontario Health Percutaneous vertebroplasty and balloon kyphoplasty for painful osteoporotic vertebral compression fractures
2025     Ontario Health Indocyanine green fluorescence imaging for colorectal surgery
2025     Ontario Health Noninvasive vagus nerve stimulation for cluster headache and migraine
2025     Ontario Health Magnetic resonance-guided focused ultrasound neurosurgery for treatment-refractory obsessive-compulsive disorder
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of home telemonitoring using specific technological follow-up systems in adult patients in the postacute phase after a transient ischemic attack, or an ischemic or hemorrhagic stroke]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Assessment of the diagnostic utility, safety, clinical efficacy and effectiveness, efficiency, and the technical and organizational aspects of artificial intelligence software for the analysis of cerebral perfusion images in acute ischemic stroke of unknown or wake-up onset]
2025     Gesundheit Osterreich GmbH (GOeG) [Health influencers: health impacts and legal framework (umbrella review)]
2025     Andalusian Health Technology Assessment Area (AETSA) [Decision-making simulator for pandemics and other disasters]
2025     Andalusian Health Technology Assessment Area (AETSA) [Outpatient detection and monitoring tools for malnutrition in cancer patients]
2025     Institute of Health Economics (IHE) Use of real world evidence to inform or augment reimbursement decisions
2025     Institute of Health Economics (IHE) Team-based primary care models: national and international approaches
2025     Institute of Health Economics (IHE) Indirect and direct non-medical costs in patients with type 2 diabetes
2025     Institute of Health Economics (IHE) Implementation of activity-based funding in acute care
2025     Institute of Health Economics (IHE) Hybrid closed loop insulin delivery systems for the treatment of diabetes
2025     Institute of Health Economics (IHE) Cost-effectiveness of antiviral drugs to prevent or treat influenza A, influenza B, or zoonotic influenza
2025     Institute of Health Economics (IHE) Comparing the use of artificial intelligence to traditional methods for study selection and data extraction in a rapid review
2025     Institute of Health Economics (IHE) Antiviral drugs for the prevention or treatment of zoonotic influenza
2025     Andalusian Health Technology Assessment Area (AETSA) [Combined use of cone beam computed tomography and other navigation techniques for the diagnosis of pulmonary nodules]
2025     Andalusian Health Technology Assessment Area (AETSA) [Guide to procedures and methods for the assessment of omics technologies / tests. Personalised precision medicine]
2025     Andalusian Health Technology Assessment Area (AETSA) [Transcranial magnetic stimulation on cerebellar ataxia: efficacy and safety. A systematic review]
2025     Andalusian Health Technology Assessment Area (AETSA) [Robotic exoskeleton-assisted upper limb rehabilitation for patients with cerebrovascular disease: efficacy and safety. A systematic review]
2025     Andalusian Health Technology Assessment Area (AETSA) [Evaluation of a multidisciplinary therapeutic approach to quality of life in patients with functional movement disorders]
2025     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of neuropsychological therapy in relation to neurological processes. Indications in the hospital setting]
2025     Andalusian Health Technology Assessment Area (AETSA) [Diagnostic accuracy and safety of Point-of-Care UltraSound (POCUS) in internal medicine outpatients]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Effectiveness and efficiency evaluation of neonatal screening for X-linked adrenoleukodystrophy]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Thermotest for the assessment of small fibre neuropathy]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Effectiveness of electrical impedance tomography in the management of critical patients with acute respiratory distress syndrome, treated with mechanical ventilation]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Effectiveness and safety of an absorbable nasal implant for the treatment of nasal obstruction caused by nasal valve collapse]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Effectiveness and safety of radiofrequency nucleolysis for chronic or acute low back pain]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Diagnostic effectiveness of rapid immunochromatographic tests for the detection of Campylobacter spp. and Salmonella spp. in patients with acute gastroenteritis]
2025     Agencia de Evaluacion de Tecnologias Sanitarias (AETS-ISCIII) [Efficacy and safety of selective posterior nasal nerve cryosurgery for the symptomatic treatment of chronic rhinosinusitis]
2025     Andalusian Health Technology Assessment Area (AETSA) [Efficacy and safety of ex vivo perfusion to assess and prepare lungs for transplantations]
2025     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Effectiveness, safety, and cost-effectiveness of prenatal serological screening for cytomegalovirus]
2025     Agency for Healthcare Research and Quality (AHRQ) Updating the framework for the Agency for Healthcare Research and Quality's National Healthcare Quality and Disparities Report
2025     Agency for Healthcare Research and Quality (AHRQ) Trauma informed care: a systematic review
2025     Agency for Healthcare Research and Quality (AHRQ) Supply chain disruption monitoring programs
2025     Agency for Healthcare Research and Quality (AHRQ) Psychosocial and pharmacologic interventions for disruptive behavior in children and adolescents
2025     Agency for Healthcare Research and Quality (AHRQ) Pharmacologic and nonpharmacologic treatments for posttraumatic stress disorder: an update of the PTSD trials standardized repository
2025     Agency for Healthcare Research and Quality (AHRQ) Peripheral nerve blocks for postoperative pain management in cardiothoracic surgery: a systematic review
2025     Agency for Healthcare Research and Quality (AHRQ) Pediatric Quality Measures Program 3.0: an evidence map of measures for vision, hearing, and developmental screening and followup
2025     Agency for Healthcare Research and Quality (AHRQ) Misuse of ADHD prescription stimulants in adults
2025     Agency for Healthcare Research and Quality (AHRQ) Mental health and occupational stress in the emergency medical services and 911 workforces
2025     Agency for Healthcare Research and Quality (AHRQ) Measure criteria for the Agency for Healthcare Research and Quality's National Healthcare Quality and Disparities Report
2025     Agency for Healthcare Research and Quality (AHRQ) Management of suicidal thoughts and behaviors in youth: a systematic review
2025     Agency for Healthcare Research and Quality (AHRQ) Making healthcare safer IV: use of structured handoff protocols for intrahospital within-unit transitions
2025     Agency for Healthcare Research and Quality (AHRQ) Making healthcare safer IV: programs for responding to harms experienced by patients during clinical care
2025     Agency for Healthcare Research and Quality (AHRQ) Living systematic review on cannabis and other plant-based treatments for chronic pain
2025     Agency for Healthcare Research and Quality (AHRQ) Interventions to prevent nonventilator hospital-acquired pneumonia
2025     Agency for Healthcare Research and Quality (AHRQ) Interventions to improve care of bereaved persons
2025     Agency for Healthcare Research and Quality (AHRQ) Implementing recommended mental health and substance use screening and counseling interventions in primary care settings for children and adolescents
2025     Agency for Healthcare Research and Quality (AHRQ) Fiber intake and laxation in people with normal bowel function
2025     Agency for Healthcare Research and Quality (AHRQ) Examining the impact of implementing high-reliability organization principles on patient safety outcomes
2025     Agency for Healthcare Research and Quality (AHRQ) Digestible carbohydrate intake and maternal-infant outcomes: a systematic review
2025     Agency for Healthcare Research and Quality (AHRQ) Comparative effectiveness of medical therapies for locally advanced gastric adenocarcinoma
2025     Agency for Healthcare Research and Quality (AHRQ) Breastfeeding and health outcomes for infants and children
2025     Agency for Healthcare Research and Quality (AHRQ) Blood-based tests for multiple cancer screening: a systematic review
2025     Agency for Healthcare Research and Quality (AHRQ) Association of digestible carbohydrate intake with cardiovascular disease, type 2 diabetes, obesity, and body composition
2025     Agency for Healthcare Research and Quality (AHRQ) Association between outcomes and dental services in people with substance use disorder: a rapid response review
2025     Agency for Healthcare Research and Quality (AHRQ) Association between outcomes and dental services in people receiving treatments that cause medication-related osteonecrosis of the jaw: a rapid response review
2025     Agency for Healthcare Research and Quality (AHRQ) Association between outcomes and dental services in people receiving treatment for human immunodeficiency virus: a rapid response review
2025     Agency for Healthcare Research and Quality (AHRQ) Association between outcomes and dental services in people at risk of post-transplant complications: a rapid response review
2025     Agency for Healthcare Research and Quality (AHRQ) Assisted home dialysis in the United States: new interest in an old idea
2025     Agency for Healthcare Research and Quality (AHRQ) Acute care nursing staff shortages that compromise patient-to-nurse ratios
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Rinvoq 45 mg, 15 mg (Crohn's disease, ulcerative colitis)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Mesh fixation device (laparoscopic inguinal hernia repair)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Drug-eluting beads]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Darzalex (multiple myeloma with ASCT)]
2025     Center for Drug Evaluation (CDE) [HTA Rapid report- Cabometyx 20, 40, 60 mg (advanced or metastatic differentiated thyroid cancer)]
2025     Austrian Institute for Health Technology Assessment (AIHTA) Long-term effectiveness and safety of enzyme replacement therapy in mucopolysaccharidosis type I, II, IVA and Pompe disease: a systematic review
2025     Austrian Institute for Health Technology Assessment (AIHTA) Dorocubicel + unexpanded CD34– cells (Zemcelpro®) for the treatment of haematological malignancies in adults
2025     WorkSafeBC Effect of ropinirole on patients with myoclonic dystonia: 2025 update
2025     WorkSafeBC Osteoarthritis of the knee and foot orthoses
2025     WorkSafeBC Cervical disc herniation and cervical spine degeneration
2025     WorkSafeBC COVID-19 vaccine and systemic lupus erythematosus (SLE)
2025     WorkSafeBC Use of supplements to treat patients diagnosed with sciatica
2025     WorkSafeBC Firefighting and Hodgkins lymphoma
2025     WorkSafeBC Hypertension and firefighting
2025     WorkSafeBC Platelet rich plasma (PRP) in treating post-fracture ankle pain
2025     WorkSafeBC External trigeminal nerve stimulation (e-TNS) in treating and preventing migraine headaches
2025     Agency for Care Effectiveness (ACE) Toripalimab for first-line systemic treatment of recurrent or metastatic nasopharyngeal carcinoma
2025     Agency for Care Effectiveness (ACE) Momelotinib for treating myelofibrosis in patients with moderate to severe anaemia
2025     Agency for Care Effectiveness (ACE) Datopotamab deruxtecan for previously treated unresectable or metastatic HR-positive, HER2-negative breast cancer
2025     Agency for Care Effectiveness (ACE) Onasemnogene abeparvovec for treating spinal muscular atrophy
2025     Agency for Care Effectiveness (ACE) Sotorasib for previously treated KRAS G12C-mutated locally advanced or metastatic non-small-cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sucroferric oxyhydroxide for treating hyperphosphataemia in patients with end-stage renal disease on dialysis
2025     Agency for Care Effectiveness (ACE) Talazoparib in combination with enzalutamide for treating HRR gene-mutated metastatic castration-resistant prostate cancer
2025     Agency for Care Effectiveness (ACE) Durvalumab with or without olaparib for treating primary advanced or recurrent endometrial cancer
2025     Agency for Care Effectiveness (ACE) Tislelizumab for treating locally advanced or metastatic non-squamous non-small-cell lung cancer without EGFR or ALK genomic tumour aberrations
2025     NIHR Health Technology Assessment programme Clinical and cost-effectiveness of technologies for the assessment of attention deficit hyperactivity disorder: a systematic review and economic model
2025     Scottish Health Technologies Group (SHTG) Digital prevention programmes for people at risk of developing type 2 diabetes
2025     Scottish Health Technologies Group (SHTG) Electrocardiogram (ECG) patch monitors for the detection of cardiac rhythm abnormalities